MetrioPharm AG Investor Relations News
-
Annual General Meeting 2014
MetrioPharm AG was delighted to welcome its shareholders on June 23, 2014, to the Annual General Meeting in Zurich.
-
MetrioPharm AG: Patent protection of MP1032
MetrioPharm AG was able to reach further goals with respect to the patent protection of MP1032.
-
Patents: Developments in all key markets
MetrioPharm AG was able to make further progress with regard to the patent protection of MP1032 in the first months of 2014.
-
MP1032 Milestones - on the route to a new drug
The most important outcome was MP1032’s superior safety profi le as confirmed by the results from the various regulatory pharmacology and toxicology studies conducted throughout the past year.